Loading...

MLTX MOONLAKE IMMUNOTHERAPEUTICS Investments/Divestments 8-K Filing

MNLK

MLTX

MOONLAKE IMMUNOTHERAPEUTICS

(MLTX)

2026 8-K

Supply Agreement Signed

Quarterly Update

Loan Agreement Update

FDA Feedback Update

Financial Results

Trial Results Update

Financial Statements

Financial Statements

Investor Meetings

Financial Results

Financial Results

Investor Presentation

Financial Results Announcement

FDA and EMA Positive Feedba...

Annual General Meeting

Earnings Report

Financial Results Announcement

Regulatory Approval

Financial Results Announcement

Phase 2 Trial Results

Filing with Quantitative Data

Compensation Increases

Financial Results Announcement

Underwriting Agreement and ...

Annual General Meeting

Quantitative Data

Quantitative Data

Financial Results Announcement

External Links:

On May 22, 2026, MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement with Vetter Pharma, agreeing on manufacturing services for their product candidate, sonelokimab, with potential pricing adjustments based on costs.

AI Assistant

MOONLAKE IMMUNOTHERAPEUTICS

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.